PCRX Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Pacira BioSciences, Inc.

Core Viewpoint - A class action lawsuit has been filed against Pacira BioSciences, Inc. for allegedly failing to disclose insufficient patent protection for its key product, Exparel, which significantly impacted its stock value [1][2][3]. Group 1: Allegations and Impact - The lawsuit claims that Pacira misled investors about the strength of its patent protections for Exparel, which is crucial for the company's growth and revenue [2][3]. - The '495 patent, which was believed to protect Exparel, was invalidated in a court ruling, leading to concerns that generic versions could enter the market, jeopardizing approximately 80% of Pacira's revenue [3]. - Following the announcement of the patent loss on August 9, 2024, Pacira's stock price plummeted from $22.36 to $11.70, a decline of over 47% in one day [3]. Group 2: Class Action Participation - Investors who purchased Pacira securities between August 2, 2023, and August 8, 2024, may be eligible to participate in the class action [1][4]. - Shareholders interested in serving as lead plaintiffs must submit their applications by March 14, 2025, but participation is not required to be eligible for recovery [4]. Group 3: Company Background - Pacira BioSciences, Inc. is an American pharmaceutical company focused on developing non-opioid pain management and regenerative health solutions [1].